Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving <scp>antifibrotic</scp> therapy

  • Yuzo Suzuki
    Second Division, Department of Internal Medicine Hamamatsu University School of Medicine Hamamatsu Japan
  • Yuya Aono
    Second Division, Department of Internal Medicine Hamamatsu University School of Medicine Hamamatsu Japan
  • Masato Kono
    Department of Respiratory Medicine Seirei Hamamatsu General Hospital Hamamatsu Japan
  • Hirotsugu Hasegawa
    Department of Respiratory Medicine Seirei Mikatahara General Hospital Hamamatsu Japan
  • Koushi Yokomura
    Department of Respiratory Medicine Seirei Mikatahara General Hospital Hamamatsu Japan
  • Hyogo Naoi
    Second Division, Department of Internal Medicine Hamamatsu University School of Medicine Hamamatsu Japan
  • Hironao Hozumi
    Second Division, Department of Internal Medicine Hamamatsu University School of Medicine Hamamatsu Japan
  • Masato Karayama
    Second Division, Department of Internal Medicine Hamamatsu University School of Medicine Hamamatsu Japan
  • Kazuki Furuhashi
    Second Division, Department of Internal Medicine Hamamatsu University School of Medicine Hamamatsu Japan
  • Noriyuki Enomoto
    Second Division, Department of Internal Medicine Hamamatsu University School of Medicine Hamamatsu Japan
  • Tomoyuki Fujisawa
    Second Division, Department of Internal Medicine Hamamatsu University School of Medicine Hamamatsu Japan
  • Yutaro Nakamura
    Second Division, Department of Internal Medicine Hamamatsu University School of Medicine Hamamatsu Japan
  • Naoki Inui
    Second Division, Department of Internal Medicine Hamamatsu University School of Medicine Hamamatsu Japan
  • Hidenori Nakamura
    Department of Respiratory Medicine Seirei Hamamatsu General Hospital Hamamatsu Japan
  • Takafumi Suda
    Second Division, Department of Internal Medicine Hamamatsu University School of Medicine Hamamatsu Japan

抄録

<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Background and objective</jats:title><jats:p>Recent research has highlighted the fundamental role of sarcopenia, characterized by loss of skeletal muscle mass and strength, with a risk of poor outcomes. AFT preserves lung function by preventing the annual decline in FVC and is associated with improved outcomes in patients with IPF. However, altered cause of death and prognostic implications of sarcopenia in patients with IPF receiving AFT remain unknown.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This study comprised two cohorts of patients with IPF receiving AFT, historical cohort of IPF patients without AFT and controls. The cause of mortality was compared with a historical cohort. Sarcopenia was assessed by measuring the ESM<jats:sub>CSA</jats:sub> and ESM<jats:sub>MA</jats:sub> via CT.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Patients with IPF had smaller ESM<jats:sub>CSA</jats:sub> and lower ESM<jats:sub>MA</jats:sub> but similar BMI than controls, suggesting patients with IPF had skeletal muscle loss without any obvious body weight loss. The most common cause of mortality in patients receiving AFT was chronic respiratory failure, accounting for approximately 60%, and decreased proportions of LC were found. Subsequently, low ESM<jats:sub>CSA</jats:sub> was an independent prognostic factor associated with worse survival rates. Furthermore, combined assessment of ESM<jats:sub>CSA</jats:sub>, %FVC predicted and BMI values provided clear prognostic distinction.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Patients with IPF receiving AFT showed skeletal muscle loss without obvious weight loss. These patients mostly died by chronic respiratory failure, and skeletal muscle wasting has prognostic significance, suggesting that preventing sarcopenia as well as preserving lung function are important for managing these patients.</jats:p></jats:sec>

収録刊行物

  • Respirology

    Respirology 26 (2), 171-179, 2020-09-23

    Wiley

被引用文献 (5)*注記

もっと見る

参考文献 (35)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ